Iopamidol Production Cost Reports

The report provides detailed analysis essential for establishing an iopamidol production plant. It encompasses all critical aspects necessary for iopamidol production, including the cost of iopamidol production, iopamidol plant cost, iopamidol production costs, and the overall iopamidol production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an iopamidol production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Iopamidol Market Analysis: Demand and Supply Analysis, and Sourcing

Iopamidol is a nonionic, water-soluble iodinated contrast agent used to make blood vessels, organs, and tissues visible on X-ray and CT scans. Its chemical name is (S)-N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodo-5-lactamidoisophthalamide, with the formula C17H22I3N3O8 and a molecular weight of 777.09. Iodine makes up about 49% of the molecule by weight, and the iodine atoms are what block X-rays, create contrast, and make the images useful. Bracco developed iopamidol and sells it as Isovue in the US and as Iopamiro in many other markets. It first reached the market decades ago and remains a workhorse agent in radiology departments around the world. It is one of the most widely used low-osmolar contrast agents, alongside iohexol, iopromide, ioversol, and iomeprol.

Demand for iopamidol comes from hospitals, imaging centers, cardiology labs, and interventional radiology suites. CT scanning is the largest use, followed by angiography, coronary procedures, urography, and venography. Rising CT volumes, aging populations, and wider access to imaging in Asia keep demand growing. China, India, and Southeast Asia have added many scanners in recent years. Supply of the API comes from Bracco in Italy and from generic producers in China, South Korea, India, and Portugal. Many of these generic manufacturers hold European or US filings and sell to injection producers that compete directly with the original brand in hospital tenders. Finished injections are made by Bracco and by many generic manufacturers in China, India, and other markets. An iopamidol demand and supply analysis must weigh iodine prices, CT procedure growth, generic competition, hospital tenders, and contrast shortages. Buyers check assay, related substances, free iodide, free aromatic amine, heavy metals, endotoxins, and optical rotation on receipt.

Summary of the Product, Grades, and Uses

Iopamidol is a white to off-white crystalline powder that dissolves freely in water. Highly concentrated solutions stay stable for long periods when protected from light, heat, and freezing. Its nonionic structure gives solutions much lower osmolality than older ionic contrast agents, which reduces pain, heat sensation, and adverse reactions. The molecule carries three iodine atoms on a benzene ring, along with hydroxyl-rich side chains that make it water-soluble and well tolerated. It is the (S) enantiomer, set by the lactic acid side chain, and specifications include optical rotation to confirm it.

Iopamidol reaches the market as an API, sterile injections in vials and bottles, and pharmacy bulk packages. Isovue is sold in four strengths: 200, 250, 300, and 370 mg of iodine per mL. These contain approximately 408-755 mg of iopamidol per mL. The solution also contains tromethamine and edetate calcium disodium, and the pH is kept between 6.5 and 7.5. At 37 degree Celsius, its osmolality ranges from around 413 to 796 mOsm/kg of water. The solution also becomes thicker as the concentration increases, with viscosity ranging from about 2 to 9.4 cP. The product is supplied in containers ranging from 30 mL vials to 150 mL bottles, with larger pharmacy bulk packs available in some markets.

Iopamidol is mainly used as a contrast agent in CT scans, angiography, urography, and venography. It helps make blood vessels and internal structures easier to see during imaging. The body removes it mainly through the kidneys, and most of the dose is excreted unchanged within about 24 hours. Doctors also give it by mouth to outline the gut on CT scans, often diluted in water.

Main End-Uses of Iopamidol

CT imaging is the main demand segment for iopamidol, covering trauma, cancer staging, stroke, and chest pain workups. Radiologists inject it to highlight blood vessels, tumors, and organs in the head, chest, abdomen, and pelvis. Each scan can use 50 to 150 mL or more of solution, so CT drives most of the volume. Buyers mainly look at price, a reliable supply, the supplier's safety record, and bottle sizes that work with their power injectors.

Angiography and cardiac procedures make up the second major end-use segment, led by coronary angiography, stent placement, and peripheral interventions. Interventional radiologists and cardiologists use iopamidol for cerebral, peripheral, visceral, and coronary arteriography and for cardiac ventriculography. Higher concentrations such as 370 mg iodine per mL give the best vessel contrast, while lower concentrations suit venography and pediatric work. These users want consistent viscosity, low reaction rates, reliable supply, and easy warming before injection.

Urography, venography, pediatric imaging, and oral CT make up the third demand segment. Iopamidol is labeled for excretory urography and CT in children as well as adults. Pediatric doses are set by body weight, age, and the type of study. Oral use outlines the stomach, small bowel, and colon on abdominal CT. Some markets also use it in myelography under local labeling, although the US label limits use to intra-arterial, intravenous, and oral routes.

Iopamidol Market Risks

Iopamidol carries market risk from fierce competition among nonionic contrast agents. Most hospitals stock two or three agents and switch based on tender results and supply. Iohexol, iopromide, ioversol, iomeprol, and iodixanol compete in the same procedures. Hospital tenders and group purchasing push prices down. National volume-based procurement in China has cut contrast prices sharply, squeezing originators, generic makers, and API suppliers. Supply shocks, such as plant shutdowns at major contrast manufacturers, can cause sudden shortages and rationing. Iodine prices fluctuate with Chilean and Japanese supply, energy costs, mining output, and demand from other users.

Iopamidol production carries its own risks because it is a complex, multistep API with tight purity limits. Iodination must be complete, and free iodide must stay low. Partially iodinated byproducts are hard to remove later, so iodine ratio, temperature, and reaction time need tight control. The chiral lactamide side chain must be added without racemization. Basic hydrolysis in older processes could cause this problem. Residual solvents, aromatic amine impurities, and color must be controlled. Most rejected lots trace back to related substances, free iodide, optical rotation, residual solvents, or endotoxin issues.

Iopamidol Production Process and Main Cost Drivers

The iopamidol production process runs from 5-aminoisophthalic acid through iodination, acid chloride formation, amidation with serinol, acylation with (S)-2-acetoxypropionyl chloride, deprotection, resin purification, crystallization, drying, and packing.

1. By Amidation and Acylation of 5-Amino-2,4,6-Triiodoisophthaloyl Dichloride: The main inputs are 5-aminoisophthalic acid, iodine or iodine monochloride, thionyl chloride, serinol, (S)-2-acetoxypropionyl chloride, dimethylacetamide, acetic anhydride, ion exchange and adsorbent resins, and alcohol solvents.

Iopamidol production starts with 5-aminoisophthalic acid, which is iodinated with iodine monochloride to give 5-amino-2,4,6-triiodoisophthalic acid. The iodinated acid is filtered, washed, and dried before the next step. Thionyl chloride converts this acid into the dichloride, known as ATIPA-Cl. This step releases sulfur dioxide and hydrogen chloride, which go to scrubbers, neutralization, and treatment. In a Bracco process, ATIPA-Cl reacts with two equivalents of serinol in dimethylacetamide with triethylamine. Acetic anhydride then protects the hydroxyl groups, giving a tetraacetyl diamide in about 90% yield.

The protected diamide is acylated with (S)-2-acetoxypropionyl chloride, giving pentaacetyl iopamidol in about 90% yield. Isopropanol quenches the excess acid chloride, and tributylamine neutralizes the acid formed in the reaction. Acid-catalyzed methanolysis then removes the acetate groups without racemizing the chiral center. The crude product passes through ion exchange and polymeric adsorbent resins and is crystallized from ethanol or acetonitrile and ethanol. The patented process reports an overall yield of 74% in this final sequence & product meets USP specifications. QC covers assay, related substances, free iodide, aromatic amine, optical rotation, and endotoxins.

Main Factors Affecting Iopamidol Production Cost

As this iopamidol production plant report shows, iopamidol production cost is mainly driven by iodine. Each kilogram of iopamidol holds about 0.49 kg of iodine, and iodine losses during iodination add more. Iodine is mainly sourced from Chile and Japan, so its price moves with a small number of suppliers. Contrast media are among the largest uses of iodine worldwide, alongside LCD films, disinfectants, and animal feed. Serinol and the chiral acid chloride are smaller but costly inputs, along with solvents, resins, and catalysts. By stoichiometry, each kilogram needs about 0.77 kg of ATIPA-Cl, 0.23 kg of serinol & 0.19 kg of (S)-2-acetoxypropionyl chloride at full yield.

Solvent recovery, purification, and regulatory requirements also affect iopamidol production costs. Recovering solvents and iodine helps reduce iopamidol production costs. The plant collects solvents such as dimethylacetamide, methanol, ethanol, and acetonitrile after use and reuses them wherever possible. During resin purification and crystallization, some product may be lost, and extra chemicals are needed to clean and reuse the resins. The plant must also spend on GMP compliance, impurity testing, and regulatory paperwork, which adds to its operating costs. Recovering iodine from waste streams can help reduce costs further. Plants treat mother liquors to free iodide and convert it back to iodine.

Raw Materials for Iopamidol Production Plant and its Procurement

Iopamidol production mainly depends on iodine and a few key chemical intermediates. Manufacturers usually buy iodine through annual supply contracts, with prices linked to market rates. Chile is the main source of iodine, which is recovered from nitrate deposits, while Japan produces it from brines found alongside natural gas. Another important raw material is 5-amin isophthalic acid, which is produced from isophthalic acid through nitration and reduction. China is a major supplier of this intermediate, with production facilities in Zhejiang, Jiangsu, and Shandong. Serinol is sourced from specialty chemical manufacturers in Europe and Asia. Its purity directly affects iopamidol impurity levels, color, and yield. (S)-2-Acetoxypropionyl chloride is made from lactic acid of the correct chirality, acetic anhydride, and a chlorinating agent.

The cheapest iodine is not always the cheapest route to good iopamidol. Iodine with impurities can lower iodination yield, add colored byproducts, and raise purification cost in every later step of the route. Serinol and acid chloride with wrong purity or chirality give impurities that are hard to remove. In practice, intermediate purity, step yields, solvent recovery, and crystallization control decide most of the cost per kilogram.

Iopamidol manufacturers manage supply through long-term iodine contracts and qualified intermediate vendors. Many generic producers buy ATIPA-Cl or other late intermediates from Chinese suppliers. Each lot is tested for assay, impurities, moisture, and chirality where relevant. Iodine recovery from mother liquors, washes, and waste reduces purchases, cost, and environmental load.

Sustainability and Regulatory Requirements

Iopamidol production raises environmental concerns centered on iodine-bearing waste, solvents, and chlorinated reagents. Regulators in Europe pay growing attention to iodinated contrast agents in surface water and drinking water sources. Iodinated contrast agents pass through patients unchanged and reach wastewater, where they resist breakdown. Some pilot projects now collect patient urine after scans to cut releases, recover iodine, and protect waterways. Plants recover iodine from mother liquors to cut waste and cost. Solvents such as dimethylacetamide, methanol, ethanol, and acetonitrile are distilled and reused. Thionyl chloride use produces sulfur dioxide and hydrogen chloride that need scrubbing with caustic, water, or both.

Regulatory obligations for iopamidol follow from its status as an injectable drug. API makers follow ICH Q7 GMP and hold US Drug Master Files or European Certificates of Suitability. Pharmacopeial monographs in the US Pharmacopeia and the European Pharmacopeia set specifications for assay, impurities, iodide, and optical rotation. Finished injections require NDA or ANDA approval, sterile GMP manufacturing, and testing for endotoxins, particles, and container integrity. The US label carries a boxed warning against intrathecal use. Labels also warn about hypersensitivity, kidney injury, and thyroid effects. Thyroid monitoring is advised in young children after exposure, especially infants, premature babies, and children with heart disease.

CAPEX and OPEX for an Iopamidol Production Plant

An iopamidol plant is a multistep API unit with large solvent and iodine handling. Most plants run campaigns that switch between several contrast agents on shared equipment. Investment starts with iodination reactors, acid chloride reactors, and scrubbers for acid gases. The plant also needs glass-lined reactors for amidation and acylation, plus distillation units and columns to recover solvents. Purification equipment includes ion exchange columns, adsorbent resin beds, crystallizers, and centrifuges. The purified product is dried under vacuum, then milled and packed in a clean room. Utilities such as steam, chilled water, nitrogen, and electricity are also required. Areas where solvents are handled need suitable explosion protection, leak detection, and fire safety systems. The quality control lab must have equipment for HPLC, chiral analysis, ion chromatography, and endotoxin testing. The site also needs solvent storage tanks, an iodine recovery unit, and warehouses.

The operating cost of an iopamidol plant depends mainly on the raw materials and the efficiency of the production process. Iodine is usually the largest raw material expense, followed by serinol, the chiral acid chloride, solvents, and resins. Other costs include staff, quality testing, wastewater treatment, and equipment maintenance. The cost per kilogram is largely affected by iodine prices, production yield, how much solvent can be recovered and reused, and how efficiently iodine is recovered. In an iopamidol production plant project report, the iopamidol plant setup cost depends on capacity, in-house intermediate production, solvent recovery scope, and GMP finishing. On the running side, the biggest cost lines are iodine, solvents, energy, and compliance. Plants that also make iohexol, iopromide, or other contrast agents spread their fixed costs better, a basic rule of industrial production economics. Shared iodination, solvent recovery, and iodine recovery units serve several products.

Plant Location and Investment Factors

An iopamidol plant is best located in an established API manufacturing area with experience in solvent handling and pharmaceutical regulations. Having local suppliers of iodine compounds and serinol can reduce transport costs and shorten delivery times. Regions such as northern Italy, Zhejiang and Jiangxi in China, South Korea, India, and Portugal have contrast media API manufacturers and may be suitable locations. The plant needs a reliable supply of iodine and other intermediates, as well as skilled chemists. It must also meet GMP requirements and have the necessary environmental permits and solvent recovery facilities. Being close to manufacturers of injectable contrast media can make product supply easier, while access to a port helps with importing iodine, receiving intermediates, and exporting the finished API.

One of the main decisions for an iopamidol project is how much of the production process to handle in-house. Producing the API from 5-aminoisophthalic acid offers greater control over impurities but requires more reactors, scrubbing systems, and investment. Producing ATIPA-Cl in-house adds iodination and acid chloride processing steps but can reduce the cost of purchased intermediates. Buying intermediates closer to the final production stage keeps the initial investment lower, although it increases dependence on suppliers. Some generic manufacturers start by purchasing these materials and add more production steps in-house as their volumes and experience grow. Another decision is whether to manufacture the finished injection as well. This requires sterile filling, terminal sterilization, and inspection equipment. For a new entrant, securing a reliable iodine supply and preparing strong Drug Master File (DMF) and Certificate of Suitability (CEP) documentation are important priorities. Long-term customers may carry out several audits, test validation batches, and submit regulatory updates before approving a new supplier.

Major Iopamidol Producing Regions

Italy has a long history of iopamidol production and is home to Bracco Imaging. China is also a major supplier of the API, with manufacturers in Zhejiang and Jiangxi holding regulatory filings in the US and Europe. Other producers are based in South Korea, India, and Portugal. Japan is an important market for contrast agents because of its widespread use of CT scans, local brands, and strict quality standards. Finished iopamidol injections are made in Germany for Bracco's US supply, while manufacturers in China, India, and other countries serve their domestic markets. API suppliers mainly sell to injectable drug manufacturers across Asia, Europe, and the Americas.

Key Iopamidol Producers

Bracco Imaging

• Italian imaging company that developed iopamidol.
• Sells Isovue and Iopamiro worldwide and holds a US DMF for the API.
• US injections are made for Bracco by BIPSO in Germany.
• Competes on brand, safety record & global imaging reach.

Zhejiang Starry Pharmaceutical

• Chinese contrast media API manufacturer holding US DMF and CEP filings for iopamidol.
• Produces several iodinated contrast APIs.
• Supplies generic injection manufacturers in China and abroad.
• Competes on cost, scale, and regulatory files.

Hovione

• Portuguese contract developer and manufacturer of APIs.
• Lists iopamidol among its products, with US and Japanese filings.
• Serves major pharma and generic customers.
• Competes on quality & regulatory track record.

Dongkook Pharmaceutical

• Korean drug producer with a strong contrast media business.
• Holds a CEP for iopamidol API.
• Supplies Korean and export markets.
• Competes on contrast expertise and quality.

Zhejiang Hisyn Pharmaceutical

• Chinese API manufacturer holding a CEP for iopamidol.
• Part of the Zhejiang contrast media cluster.
• Supplies generic injection manufacturers.
• Competes on price & European access.

Jiangxi Brother Pharmaceutical

• Chinese API producer holding a CEP for iopamidol.
• Focuses on contrast media and related intermediates.
• Exports to regulated and emerging markets.
• Competes on cost, with grade claims to be verified lot by lot.